Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing
Posted:
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.
Read the full article in the latest MedCity News blog post here.
A study suggests that artificial intelligence (AI) showed comparable performance to dermatologists in detecting melanoma, with similar sensitivity and specificity in prospective clinical studies.
Experts often consider melanoma to be the most serious type of skin cancer due to the likelihood of metastasizing.
Read more here.
The further Apple dives into medical technology, the more it will have to deal with regulators. Now, the App Store will label apps that meet select criteria for medical devices in the US, EU, and UK.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us